BlinkLab Launches Pivotal FDA Trial for Autism Diagnostic Aid

A Major Step Toward FDA Approval

BlinkLab Limited (ASX:BB1) has taken a significant stride forward in its quest to bring a novel autism diagnostic aid to market, announcing the enrolment and successful testing of the first participant in its pivotal FDA 510(k) validation study. This milestone marks the official commencement of the clinical validation program for BlinkLab Dx1, a smartphone-based diagnostic platform designed to assist clinicians in identifying autism in children more accurately and earlier than traditional methods.

The study is being conducted under the guidance of IQVIA-MCRA, a globally recognised contract research organisation, ensuring rigorous adherence to FDA protocols and data integrity. The trial involves a double-blinded, multi-centre design across 10 prominent US clinical sites, including Cincinnati Children’s Hospital and Seattle Children’s Hospital, representing a geographically and demographically diverse patient population.

Building on Strong Pilot Results

This pivotal validation follows a successful pilot study involving 485 participants, where BlinkLab Dx1 demonstrated diagnostic sensitivity of 83.7% and specificity of 84.7%, comfortably exceeding the FDA’s target thresholds of 65% for both metrics. These promising results underpin the company’s confidence in the device’s potential to transform autism assessment by combining objective digital biomarkers with clinician expertise.

The current study includes an initial usability phase to confirm that clinicians and caregivers can effectively operate the BlinkLab platform and interpret its outputs in real-world settings. This phase will transition seamlessly into the clinical validation phase, which will compare BlinkLab Dx1’s diagnostic performance against established gold-standard clinical assessments.

Clear Regulatory Pathway and Timeline

Participant recruitment is expected to take around eight months, with BlinkLab targeting submission of its 510(k) regulatory package to the FDA by the end of 2026. The company emphasises that BlinkLab Dx1 is intended as an aid to clinical decision-making rather than a replacement, aiming to support earlier and more accessible autism diagnosis during critical developmental periods.

CEO Dr Henk-Jan Boele highlighted the importance of this milestone, describing it as the most significant in BlinkLab’s history. He noted the years of development, testing, and regulatory engagement that have culminated in this pivotal study, expressing optimism about the device’s potential to reshape clinical practice in autism assessment.

With a robust clinical trial network now fully established and underway, BlinkLab is positioning itself at the forefront of digital health innovation in neurodevelopmental diagnostics.